TRIB earnings

Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025 Reiterates guidance to achieve 2024 sales revenue for TrinScreen HIV of approximately $10 million DUBLIN, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company's results for t

DUBLIN, Ireland, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the third quarter 2024 on Friday, November 15, 2024 and host a conference call at 10:00 AM ET. Conference Call Dial-In & Webcast Information Date:Friday, November 15, 2024Time:10:00 AM ETUnited States:1-877-407-0784International:1-201-689-8560Conference ID: Webcast: Call me™:13750164 click here https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6 About Trinity Biotech

-Q2, 2024 total revenues of $15.8 million grew +14% Y/Y and +7.7% Q/Q based on strong demand and output in the TrinScreen HIV business- -Point-of-Care product revenue of $4.6 million grew 119% Y/Y and +53% Q/Q- -Reiterating guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2, 2025- DUBLIN, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company's results for the quarter ended June 30, 2024. Existing Business - Key Highl

DUBLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the second quarter 2024 on Wednesday, August 14, 2024 at 8:30 AM ET. Conference Call Dial-In & Webcast Information Date:Wednesday, August 14, 2024Time:8:30 AM ETUnited States:1-877-407-0784International:1- 201-689-8560Conference ID:13748426Webcast:webcast linkCall me™:https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6   About Trinity Biotech Trinity Biotech is a commercial stage

-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025- -Strong sequential 39% Q/Q growth on Point-of-Care revenues associated with successful rollout and scaling of HIV test production- -Disciplined execution of operational efficiencies led to 3.6 percentage point Q/Q increase in gross margin percentage with further improvements expected through 2024 and into early 2025- DUBLIN, Ireland, May 23, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable bi

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET. Conference Call Dial-In & Webcast Information Date:Thursday, May 23, 2024Time:8:30 AM ETUnited States:1-877-407-0784International:1- 201-689-8560Conference ID: Webcast:Call me™:13746798webcast linkhttps://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6  About Trinity Biotech Trinity Biotech is a com

DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company"), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET. Conference Call Dial-In & Webcast Information Date:Thursday, April 4, 2024Time:8:00 AM ETUnited States:1-877-407-0784International:1-201-689-8560Conference ID:13745604Call me™:https://callme.viavid.com/viavid/?callme=true&passcode=13743417&h=true&info=company-email&r=true&B=6WebcastClick here for webcast   About Trinity Biotech Trinity Biotech develops, a

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) today announced the Company's results for the quarter ended September 30, 2023. Business Updates and Strategic Priorities In December 2023, the Company announced the promotion of John Gillard from CFO to CEO and the promotion of Des Fitzgerald to the role of Interim CFO. The new management team has now put in place a clear set of strategies and priorities as set out below. Biosensor technology acquisition The Company has today announced the acquisition of the biosensor assets of Waveform Technologies Inc. ("Waveform") for $12.5 million in cash and 9 million American Depositary Shares ("ADS") plus con

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company") today announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring ("CGM") biosensor device in China and India. This Letter of Intent is related to the Company's recently announced acquisition of the CGM assets of Waveform Technologies, Inc.  Trinity has entered into a Letter of Intent with Bayer's subsidiary in China under which both parties confirmed their intent to further explore an exclusive joint partnership between the Company and Bayer for the launch of a CGM focused biosensor device into the Chinese market (the "Chi

-Repositioning to a rapidly expanding biosensor market with potential for significant growth for the company as part of a revised strategy under our new management -Upfront payment of $12.5 million cash and 9 million ADSs -Strengthened investment relationship with Perceptive Advisors with the entry into an increased senior secured term loan credit facility with lower interest rates and Perceptive Advisors taking an approximately 20% equity interest in Trinity -Investor call to be held today at 8:30 am EST DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company") today announced it has entered into a definitive agreement to acquire the biosenso

DUBLIN, Ireland, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company"), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will host an investor call on Wednesday, January 31 at 8:30 AM ET to provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, January 31, 2024Time:8:30 AM ETUnited States:1-877-407-0784International:1-201-689-8560Conference ID:13744109Webcast:Click Here for WebcastCallMe™:Click Here for CallMe Feature About Trinity Biotech Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents a

DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended June 30, 2023. Summary Highlights: Revenue: Total revenue for fiscal Q2, 2023 was $13.9m (excluding Fitzgerald Industries, which was disposed of in April 2023). Excluding our Covid focused PCR Viral Transport Media ("VTM") products and Fitzgerald Industries, revenue for the quarter of $13.7m was 3% lower than in Q1, 2023.Our core franchise Diabetes consumables revenues increased 10% over Q1, 2023.Recurring Diabetes consumables rev

DUBLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2023 on Tuesday, October 3, 2023. The Company has scheduled a conference call for that same day, Tuesday, October 3, 2023 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.         Interested parties can access the call by dialing: US Toll Free:1-844-861-5499International Toll:1-412-317-6581Ireland Toll:014311269Ireland Toll Free:1800932830Please ask to be joined into the Trinity Biotech call.   A simultaneous webcast o

DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended March 31, 2023. Summary Highlights: Revenue/Margin: Total revenue for fiscal Q1, 2023 was $17.2m. Excluding our Covid focused PCR Viral Transport Media ("VTM") products and Fitzgerald Industries (which was disposed in April 2023), revenue for the quarter of $14m was 2.0% higher than in Q1, 2022.Our performance in the quarter was led by year over year growth of approximately 35%, 15% and 10% respectively for our Autoimm

DUBLIN, July 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2023 on Thursday, July 6, 2023. The Company has scheduled a conference call for that same day, July 6, 2023 at 11:00am ET (16:00pm BST) to discuss the results of the quarter. Interested parties can access the call by dialing: US Toll Free:  1-844-861-5499 International Toll: 1-412-317-6581 Ireland Toll:014311269 Ireland Toll Free:   1800932830Please ask to be joined into the Trinity Biotech call.  A simultaneous webcast of the call can be

DUBLIN, Ireland, March 16, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2022 on Thursday, March 23, 2023. The Company has scheduled a conference call for that same day, March 23, 2023 at 10:00am ET (14:00pm GMT) to discuss the results of the quarter. Interested parties can access the call by dialing:US Toll Free:1-844-861-5499International Toll:1-412-317-6581Ireland Toll:014311269Ireland Toll Free:1800932830Please ask to be joined into the Trinity Biotech call. A simultaneous webcast of the cal

DUBLIN, Ireland, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended September 30, 2022. Summary Highlights: Total revenues for Q3 2022 were $19.5m. Excluding our Covid focused PCR Viral Transport Media ("VTM") products, Q3 2022 revenues of $19.2m were marginally higher by 2% compared to Q3 2021 and were up 6% compared to Q2 2022.A strong YoY 30% increase in revenues attributable to both our Haemoglobins and Fitzgerald Industries Life Sciences businesses offset the timing impact of atypically concen

DUBLIN, Ireland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter fiscal year 2022 on Thursday, December 15, 2022. The Company has scheduled a conference call for that same day, December 15, 2022 at 11:00am ET (16:00pm GMT) to discuss the results of the quarter. Interested parties can access the call by dialing:US Toll Free:1-844-861-5499International Toll:1-412-317-6581Ireland Toll:014311269Ireland Toll Free:1800932830Please ask to be joined into the Trinity Biotech call. A simultaneous webcast of the c

DUBLIN, Ireland, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended June 30, 2022 and preliminary guidance with respect to Q3 revenues. Summary Highlights: Total revenues for Q2 2022 were $18.5m.Excluding our Covid focused PCR Viral Transport Media ("VTM") products, Q2 2022 revenues of $18.0m were broadly flat compared to Q2 2021 and were up 7% compared to Q1 2022. A strong YoY increase in revenues in our diabetes A1c product line revenues of over 25% offset a decline in legacy infectious disease p

DUBLIN, Ireland, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2022 on Thursday, November 3, 2022. The Company has scheduled a conference call for that same day, November 3, 2022 at 11:00am ET (3:00pm GMT) to discuss the results of the quarter. Interested parties can access the call by dialing: US Toll Free:1-844-861-5499 International Toll: 1-412-317-6581 Ireland Toll:014311269 Ireland Toll Free: 1800932830Please ask to be joined into the Trinity Biotech call. A simultaneous webcast of the

DUBLIN, Ireland, June 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company's results for the quarter ended March 31, 2022. Quarter 1 Results Total revenues for Q1, 2022 were $18.8m compared to $25.6m in Q1, 2021, a decrease of 26.6% as indicated below:  2021Quarter 12022Quarter 1Increase/(Decrease) $'000$'000%Point-of-Care1,8882,16414.6%Clinical Laboratory23,70616,612(29.9%)Total25,59418,776(26.6%) Point-of-Care revenues for Q1, 2022 increased to $2.2m from $1.9m in Q1, 2021, an increase of 14.6%. This increase was mainly attributable t

DUBLIN, Ireland, June 29, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2022 on Thursday, June 30, 2022. The Company has scheduled a conference call for that same day, Thursday June 30, 2022 at 11:00am ET (4:00pm BST) to discuss the results of the quarter. Interested parties can access the call by dialing: US Toll Free:1-844-861-5499 International Toll:1-412-317-6581 Ireland Toll:014311269 Ireland Toll Free:1800932830Please ask to be joined into the Trinity Biotech call.A simultaneous webcast of the

DUBLIN, Ireland, April 11, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2021 and fiscal year 2021. Fiscal Year 2021 Results Total revenues for fiscal year 2021 were $93.0m compared to $102.0m in 2020, a decrease of 8.8% year on year and were broken down as follows:    Full Year2020Full Year2021Increase/(decrease) US$'000US$'000%Point-of-Care9,21510,33712.2%     Clinical Laboratory92,76582,628(10.9%)     Total101,98092,965(8.8%)  Point-of-Care revenues increased from $9.2m in 2020 to $10.3m in 2021, whi

DUBLIN, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) (the "Company"), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the Company's subsidiary, Trinity Biotech Investment Limited (the "Notes"), and exchange agreements for over 99.7% of the outstanding Notes, all subject to certain conditions precedent. Quarter 3 2021 Results          Total revenues for Q3, 2021 were $22.0m, which compares to $32.0m in Q3, 2020, a

DUBLIN, Ireland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2021. Quarter 2 ResultsTotal revenues for Q2, 2021 were $25.8m, which compares to $16.0m in Q2, 2020, an increase of $9.8m and which were broken down as follows:  2020Quarter 22021Quarter 2 Increase US$'000US$'000%Point-of-Care1,2671,95854.5% Clinical Laboratory14,75723,88561.9% Total16,02425,84361.3%  Point-of-Care revenues for Q2, 2021 increased from $1.3m to $2.0m when compared to Q2, 2020, an increase of almost 55%. This increase wa

DUBLIN, Ireland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2021 on Thursday, September 9, 2021. The Company has scheduled a conference call for that same day, Thursday September 9, 2021 at 11:00am ET (4:00pm BST) to discuss the results of the quarter. Interested parties can access the call by dialing: US Toll Free:1-844-861-5499International Toll:1-412-317-6581Ireland Toll: 014311269Ireland Toll Free: 1800932830 Please ask to be joined into the Trinity Biotech call. A simu

DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2021. Quarter 1 Results Total revenues for Q1, 2021 were $25.6m which compares to $21.2m in Q1, 2020, an increase of 20.9% and which were broken down as follows:  2020Quarter 12021Quarter 1Increase/(decrease) US$'000US$'000%Point-of-Care3,3351,888(43.4%)Clinical Laboratory17,84223,70632.9%Total21,17725,59420.9% Point-of-Care revenues for Q1, 2021 decreased from $3.3m to $1.9m when compared to Q1, 2020, a decrease of 43.4%. This was p

DUBLIN, Ireland, March 25, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended December 31, 2020 and fiscal year 2020. Fiscal Year 2020 Results Total revenues for fiscal year 2020 were $102m versus $90.4m in 2019, an increase of 12.8% year on year and were broken down as follows:  Full Year 2019Full Year 2020Increase/ (decrease) US$’000US$’000%Point-of-Care11,3939,215(19.1%)    Clinical Laboratory79,04292,76517.4%    Total90,435101,98012.80% Point-of-Care revenues decreased from $11.4m in 2019 to $9.2m in 2020, which